SCHEMBL2828199

SCHEMBL2828199

COc1cccc(C=Cc2nc3ccccn3c2C(=O)O)c1OCC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 2/20 0.40
PIM2 Q9P1W9 2/20 0.40
ACMSD Q8TDX5 1/20 0.39
MAPT P10636 4/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
KDM4E B2RXH2 3/20 0.39
KMT2A Q03164 2/20 0.39
ALDH1A1 P00352 2/20 0.39
POLB P06746 2/20 0.39
MAPK1 P28482 2/20 0.39
MEN1 O00255 1/20 0.39
NFE2L2 Q16236 3/20 0.37
LMNA P02545 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
DAPK3 O43293 1/20 0.36
JAK2 O60674 1/20 0.36
PRKD3 O94806 1/20 0.36
MAP4K4 O95819 1/20 0.36
ABL1 P00519 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2828198 1.00 PIM1 (0.40) PIM1PIM2ACMSDMAPTNPC1
SCHEMBL2823725 0.89 PIM1 (0.40) PIM1PIM2NPC1RAB9AKDM4E
SCHEMBL2823729 0.89 PIM1 (0.40) PIM1PIM2NPC1RAB9AKDM4E
SCHEMBL2827667 0.89 MAPK1 (0.48) PIM1PIM2MAPTNPC1RAB9A
SCHEMBL2827670 0.89 MAPK1 (0.48) PIM1PIM2MAPTNPC1RAB9A
SCHEMBL2829776 0.87 ACMSD (0.38) ACMSDMAPTNPC1RAB9AKDM4E
SCHEMBL2824759 0.84 ACMSD (0.38) ACMSDMAPTNPC1RAB9AKDM4E
SCHEMBL2824763 0.84 ACMSD (0.38) ACMSDMAPTNPC1RAB9AKDM4E
SCHEMBL13287324 0.83 NPC1 (0.46) MAPTNPC1RAB9AKDM4EKMT2A
SCHEMBL2830605 0.80 MAPK1 (0.46) PIM1PIM2MAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318928-B2 Fused imidazole carboxamides as TRPV3 modulators GLENMARK PHARMACEUTICALS, S.A. (CH) 2012-11-27 US disclosed
US-20100152192-A1 FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS S.A (CH) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152192-A1 FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS TRPV3, TRPV1, TRPV2 PIM1 3427/4885PIM2 2576/4885ACMSD 1516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.